{"commentary":{"count":36,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":21,"youtube":10,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05884398\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"LIBERTAS","nct_id":"NCT05884398","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=libertas-nct05884398. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"LIBERTAS","arms":[{"description":"Participants with PSA level \\<0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and treated with apalutamide with intermittent ADT per protocol or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) and followed up for up to a maximum of 2 years after the main treatment phase, or until death, withdrawal of consent, loss to follow-up, early termination of the study by the sponsor for any reason, whichever occurs first.","label":"Arm A (Intermittent ADT Group)","type":"EXPERIMENTAL"},{"description":"Participants with PSA level \\<0.2 ng/mL after 6 months of treatment with Apalutamide and ADT during initial treatment phase, will enter main treatment phase and continue to receive apalutamide plus ADT or followed up for at least 18 months from Day 1 of Cycle 7 (each cycle 28 days) and followed up for up to a maximum of 2 years after the main treatment phase, or until death, withdrawal of consent, loss to follow-up, early termination of the study by the sponsor for any reason, whichever occurs first.","label":"Arm B (Continuous ADT Group)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-10-12","type":"ESTIMATED"},"conditions":["Metastatic Castrate-sensitive Prostate Cancer"],"enrollment":{"count":420,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Apalutamide","type":"DRUG"},{"name":"Androgen-deprivation Therapy (ADT)","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-10-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)","timeFrame":"From randomization (Day 1 of Cycle 7) up to 18 months"},{"measure":"Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months","timeFrame":"From randomization (Day 1 of Cycle 7) up to 18 months"}],"references":[],"start_date":{"date":"2023-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","url":"https://clinicaltrials.gov/study/NCT05884398"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/libertas-nct05884398"}